Primary breast tumors have predominantly been reported to be ER+/PR+/HER2-, which determine the basis of applying therapeutics, including radiation therapy, surgery, and endocrine therapies (e.g., anti-estrogen therapy) (Klinge, 2018). This evidence concerns the gene ERBB2 and breast neoplasm.